Maternal serum adropin as a potential biomarker for placenta accreta spectrum: a cross-sectional study
Seray Sırkıntı, Gulsum Uysal, Sule Gül Aydın, Merve Vay Bedir · 2026
Read Maternal serum adropin as a potential biomarker for placenta accreta spectrum: a cross-sectional study by Seray Sırkıntı, Gulsum Uysal, Sule Gül Aydın, Merve Vay Bedir (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13455208.txt.
Description
Seray Sırkıntı and others tested mum blood adropin as a flag for placenta accreta range in 2026, in a cross-section study. Adropin is a body peptide tied to vessel lining health, and low blood levels go with lining harm and poor vessel remodelling. The team set adropin in mums with placenta previa or accreta range next to healthy mums.
Eighty-four single-baby pregnancies at thirty-four weeks or more made the cut: forty-two with previa or accreta range and forty-two healthy mums set for caesarean birth. Pre-op mum blood adropin was scored by enzyme-linked assay, with mum traits, birth traits, scan traits, and op traits logged. ROC curve tests scored how well adropin tells apart odd placental invasion. The study tests if a blood peptide can flag risky placental invasion before birth.
Catalog record
| CREATOR | Seray Sırkıntı, Gulsum Uysal, Sule Gül Aydın, Merve Vay Bedir |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |